-
1
-
-
1642307340
-
Endostatin's antiangiogenic signaling network
-
DOI 10.1016/S1097-2765(04)00102-9, PII S1097276504001029
-
A Abdollahi P Hahnfeldt C Maercker HJ Gröne J Debus W Ansorge J Folkman L Hlatky PE Huber 2004 Endostatin's antiangiogenic signaling network Mol Cell 13 649 663 1:CAS:528:DC%2BD2cXis1Kktbk%3D 10.1016/S1097-2765(04)00102-9 15023336 (Pubitemid 38368123)
-
(2004)
Molecular Cell
, vol.13
, Issue.5
, pp. 649-663
-
-
Abdollahi, A.1
Hahnfeldt, P.2
Maercker, C.3
Grone, H.-J.4
Debus, J.5
Ansorge, W.6
Folkman, J.7
Hlatky, L.8
Huber, P.E.9
-
2
-
-
0035985171
-
Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients
-
DOI 10.1016/S0169-5002(02)00027-2, PII S0169500202000272
-
D Brattström M Bergqvist P Hesselius A Larsson K Lamberg J Wernlund O Brodin G Wagenius 2002 Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumors and poorer survival in non-small cell lung cancer patients Lung Cancer 37 57 63 10.1016/S0169-5002(02)00027-2 12057868 (Pubitemid 34621459)
-
(2002)
Lung Cancer
, vol.37
, Issue.1
, pp. 57-63
-
-
Brattstrom, D.1
Bergqvist, M.2
Hesselius, P.3
Larsson, A.4
Lamberg, K.5
Wernlund, J.6
Brodin, O.7
Wagenius, G.8
-
3
-
-
0034032882
-
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
-
1:CAS:528:DC%2BD3cXisVynurk%3D 10766175
-
T Browder CE Butterfield BM Kraling B Shi B Marshall MS O'Reilly J Folkman 2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886 1:CAS:528: DC%2BD3cXisVynurk%3D 10766175
-
(2000)
Cancer Res
, vol.60
, pp. 1878-1886
-
-
Browder, T.1
Butterfield, C.E.2
Kraling, B.M.3
Shi, B.4
Marshall, B.5
O'Reilly, M.S.6
Folkman, J.7
-
4
-
-
0035049240
-
Endogenous angiogenesis inhibitors and their therapeutic implications
-
DOI 10.1016/S1357-2725(01)00023-1, PII S1357272501000231
-
Y Cao 2001 Endogenous angiogenesis inhibitors and their therapeutic and their therapeutic implications Int J Biochem Cell Biol 33 357 369 1:CAS:528:DC%2BD3MXislGgtrg%3D 10.1016/S1357-2725(01)00023-1 11312106 (Pubitemid 32324004)
-
(2001)
International Journal of Biochemistry and Cell Biology
, vol.33
, Issue.4
, pp. 357-369
-
-
Cao, Y.1
-
5
-
-
0036225350
-
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels
-
1:STN:280:DC%2BD387islyksw%3D%3D 10.1093/annonc/mdf013 11863115
-
M Colleoni A Rocca MT Sandri L Zorzino G Masci F Nole G Peruzzotti C Robertson L Orlando S Cinieri F de Braud G Viale A Goldhirsch 2002 Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 73 80 1:STN:280:DC%2BD387islyksw%3D%3D 10.1093/annonc/mdf013 11863115
-
(2002)
Ann Oncol
, vol.13
, pp. 73-80
-
-
Colleoni, M.1
Rocca, A.2
Sandri, M.T.3
Zorzino, L.4
Masci, G.5
Nole, F.6
Peruzzotti, G.7
Robertson, C.8
Orlando, L.9
Cinieri, S.10
De Braud, F.11
Viale, G.12
Goldhirsch, A.13
-
6
-
-
20044371835
-
Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival
-
DOI 10.1081/CNV-200055949
-
AZ Dudek H Mahaseth 2005 Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival Cancer Invest 23 193 200 1:CAS:528:DC%2BD2MXkslyhu7s%3D 10.1081/CNV-200055949 15945504 (Pubitemid 40770736)
-
(2005)
Cancer Investigation
, vol.23
, Issue.3
, pp. 193-200
-
-
Dudek, A.Z.1
Mahaseth, H.2
-
7
-
-
21344453004
-
Pharmacogenetics for individualized cancer chemotherapy
-
DOI 10.1016/j.pharmthera.2005.02.005, PII S0163725805000574
-
T Efferth M Volm 2005 Pharmacogenetics for individualized cancer chemotherapy Pharmacol Ther 107 155 176 1:CAS:528:DC%2BD2MXlvVWgtLs%3D 10.1016/j.pharmthera.2005.02.005 15890408 (Pubitemid 40910039)
-
(2005)
Pharmacology and Therapeutics
, vol.107
, Issue.2
, pp. 155-176
-
-
Efferth, T.1
Volm, M.2
-
8
-
-
0038779877
-
Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia
-
DOI 10.1080/0962935031000134888
-
J Gora-Tybor JZ Bloski T Robak 2003 Circulating proangiogenic cytokines and angiogenesis inhibitor in untreatment patients with chronic lymphocytic leukemia Med Inflamm 12 167 171 1:CAS:528:DC%2BD3sXltlWnsb4%3D 10.1080/0962935031000134888 (Pubitemid 36871852)
-
(2003)
Mediators of Inflammation
, vol.12
, Issue.3
, pp. 167-171
-
-
Gora-Tybor, J.1
Blonski, J.Z.2
Robak, T.3
-
9
-
-
33750455512
-
Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer?
-
DOI 10.1159/000096072
-
AM Granato GL Frassineti N Giovannini M Ballardini O Nanni R Maltono D Amadori A Volpi 2006 Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer? Tumor Biol 27 302 308 1:CAS:528:DC%2BD28XhtFaks7rM 10.1159/000096072 (Pubitemid 44646224)
-
(2006)
Tumor Biology
, vol.27
, Issue.6
, pp. 302-308
-
-
Granato, A.M.1
Frassineti, G.L.2
Giovannini, N.3
Ballardini, M.4
Nanni, O.5
Maltoni, R.6
Amadori, D.7
Volpi, A.8
-
10
-
-
0030576517
-
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
-
DOI 10.1016/S0092-8674(00)80108-7
-
D Hanahan J Folkman 1996 Patterns and emerging mechanism of the angiogenic switch during tumorigenesis Cell 86 353 364 1:CAS:528: DyaK28XltVSks7s%3D 10.1016/S0092-8674(00)80108-7 8756718 (Pubitemid 26272076)
-
(1996)
Cell
, vol.86
, Issue.3
, pp. 353-364
-
-
Hanahan, D.1
Folkman, J.2
-
11
-
-
34548542204
-
Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer?
-
1:CAS:528:DC%2BD2sXpsFGlt7c%3D 17611658
-
Y Inoue E Ojima J Watanabe Hiro Y Toiyama M Kobayashi C Miki M Kusunoki 2007 Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer? Oncol Rep 18 369 375 1:CAS:528:DC%2BD2sXpsFGlt7c%3D 17611658
-
(2007)
Oncol Rep
, vol.18
, pp. 369-375
-
-
Inoue, Y.1
Ojima, E.2
Watanabe Hiro, J.3
Toiyama, Y.4
Kobayashi, M.5
Miki, C.6
Kusunoki, M.7
-
12
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
1:CAS:528:DC%2BD2cXpsVWru7Y%3D 10.1200/JCO.2003.10.066 12506171
-
F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 1:CAS:528: DC%2BD2cXpsVWru7Y%3D 10.1200/JCO.2003.10.066 12506171
-
(2003)
J Clin Oncol
, vol.21
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
Meropol, N.J.4
Novotny, W.F.5
Lieberman, G.6
Griffing, S.7
Bergsland, E.8
-
13
-
-
0037426605
-
Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis
-
DOI 10.1016/S0304-3835(03)00047-8
-
AJ Karayiannakis H Bolanaki KN Syrigos B Asimakopoulos A Polychronidis S Anagnostoulis C Simopoulos 2003 Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis Cancer Lett 194 119 124 1:CAS:528:DC%2BD3sXjtFCjsLg%3D 10.1016/S0304-3835(03)00047-8 12706865 (Pubitemid 36428891)
-
(2003)
Cancer Letters
, vol.194
, Issue.1
, pp. 119-124
-
-
Karayiannakis, A.J.1
Bolanaki, H.2
Syrigos, K.N.3
Asimakopoulos, B.4
Polychronidis, A.5
Anagnostoulis, S.6
Simopoulos, C.7
-
14
-
-
0034989971
-
Vascular endothelial growth factor serum concentration changes during chemotherapy in patients with lung cancer
-
1:CAS:528:DC%2BD3MXmtVOnu78%3D 11402619
-
Y Kido 2001 Vascular endothelial growth factor serum concentration changes during chemotherapy in patients with lung cancer Kurume Med J 48 43 47 1:CAS:528:DC%2BD3MXmtVOnu78%3D 11402619
-
(2001)
Kurume Med J
, vol.48
, pp. 43-47
-
-
Kido, Y.1
-
15
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
-
1:CAS:528:DC%2BD3cXisFOlurc%3D 10.1172/JCI8829 10772661
-
G Klement S Baruchel J Rak S Man K Clark DJ Hicklin P Bohlen RS Kerbel 2000 Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Investig 105 R15 R24 1:CAS:528:DC%2BD3cXisFOlurc%3D 10.1172/JCI8829 10772661
-
(2000)
J Clin Investig
, vol.105
-
-
Klement, G.1
Baruchel, S.2
Rak, J.3
Man, S.4
Clark, K.5
Hicklin, D.J.6
Bohlen, P.7
Kerbel, R.S.8
-
16
-
-
0034219424
-
Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen?
-
1:CAS:528:DC%2BD3cXksV2qsr4%3D 10853032
-
JK Lee YJ Hong CJ Han DY Hwang SI Hong 2000 Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol 17 149 152 1:CAS:528:DC%2BD3cXksV2qsr4%3D 10853032
-
(2000)
Int J Oncol
, vol.17
, pp. 149-152
-
-
Lee, J.K.1
Hong, Y.J.2
Han, C.J.3
Hwang, D.Y.4
Hong, S.I.5
-
17
-
-
0034521483
-
Chemotherapy and angiogenesis in advanced cancer: Vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer
-
1:CAS:528:DC%2BD3MXktVyktg%3D%3D
-
P Lissoni E Fugamalli A Ardizzoia S Secondino G Tancini GS Gardani 2000 Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer Int J Biol Marker 15 308 311 1:CAS:528: DC%2BD3MXktVyktg%3D%3D
-
(2000)
Int J Biol Marker
, vol.15
, pp. 308-311
-
-
Lissoni, P.1
Fugamalli, E.2
Ardizzoia, A.3
Secondino, S.4
Tancini, G.5
Gardani, G.S.6
-
18
-
-
78751617744
-
Angiogenesis and vascular endothelial growth factor expression in invasive breast carcinomas after primary chemotherapy
-
FQ Meng L Li JM Zhang HY Wu JJ Nie 2001 Angiogenesis and vascular endothelial growth factor expression in invasive breast carcinomas after primary chemotherapy Chin Oncol 11 444 446
-
(2001)
Chin Oncol
, vol.11
, pp. 444-446
-
-
Meng, F.Q.1
Li, L.2
Zhang, J.M.3
Wu, H.Y.4
Nie, J.J.5
-
19
-
-
0031454617
-
Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
-
DOI 10.1016/S0092-8674(00)81848-6
-
MS O'Reilly T Boehm Y Shing N Fukai G Vasios WS Lane E Flynn JR Birkhead BR Olsen J Folkman 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277 285 10.1016/S0092-8674(00)81848-6 9008168 (Pubitemid 28015876)
-
(1997)
Cell
, vol.88
, Issue.2
, pp. 277-285
-
-
O'Reilly, M.S.1
Boehm, T.2
Shing, Y.3
Fukai, N.4
Vasios, G.5
Lane, W.S.6
Flynn, E.7
Birkhead, J.R.8
Olsen, B.R.9
Folkman, J.10
-
20
-
-
22244452376
-
VEGF-targeted therapy: Therapeutic potential and recent advances
-
DOI 10.1634/theoncologist.10-6-382
-
LS Rosen 2005 VEGF-targeted therapeutic potential and recent advances Oncologist 10 75 82 10.1634/theoncologist.10-6-382 (Pubitemid 40993566)
-
(2005)
Oncologist
, vol.10
, Issue.6
, pp. 382-391
-
-
Rosen, L.S.1
-
21
-
-
61449210829
-
Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast
-
1:CAS:528:DC%2BD1MXitlWgtLc%3D 10.1007/s00432-008-0497-9 18936974
-
S Shivakumar BT Prabhakar K Jayashree MG Rajan BP Salimath 2009 Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast J Cancer Res Clin Oncol 135 4 627 636 1:CAS:528:DC%2BD1MXitlWgtLc%3D 10.1007/s00432-008-0497-9 18936974
-
(2009)
J Cancer Res Clin Oncol
, vol.135
, Issue.4
, pp. 627-636
-
-
Shivakumar, S.1
Prabhakar, B.T.2
Jayashree, K.3
Rajan, M.G.4
Salimath, B.P.5
-
22
-
-
39749118576
-
Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer
-
DOI 10.1007/s00280-007-0526-4
-
F Tas D Duranyildz HO Soydinc I Cicin M Selam K Uygun R Disci V Yasasever E Topuz 2008 Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer Cancer Chemother Pharmacol 61 721 725 1:CAS:528:DC%2BD1cXitleru7w%3D 10.1007/s00280-007-0526-4 17554539 (Pubitemid 351302027)
-
(2008)
Cancer Chemotherapy and Pharmacology
, vol.61
, Issue.5
, pp. 721-725
-
-
Tas, F.1
Duranyildiz, D.2
Soydinc, H.O.3
Cicin, I.4
Selam, M.5
Uygun, K.6
Disci, R.7
Yasasever, V.8
Topuz, E.9
-
23
-
-
36849048282
-
Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
-
DOI 10.1007/s00432-007-0251-8
-
P Terheyden MA Hofmann M Weininger FB Bröcker JC Becker 2007 Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma J Cancer Res Clin Oncol 133 11 897 901 1:CAS:528:DC%2BD2sXhtVWjsbvK 10.1007/s00432-007-0251-8 17583821 (Pubitemid 350218914)
-
(2007)
Journal of Cancer Research and Clinical Oncology
, vol.133
, Issue.11
, pp. 897-901
-
-
Terheyden, P.1
Hofmann, M.A.2
Weininger, M.3
Brocker, E.-B.4
Becker, J.C.5
-
24
-
-
0023719442
-
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer
-
1:STN:280:DyaL1c3ltlaruw%3D%3D 3164256
-
C Tondini DF Hayes R Gelman IC Henderson DW Kufe 1988 Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer Cancer Res 48 4107 4112 1:STN:280:DyaL1c3ltlaruw%3D%3D 3164256
-
(1988)
Cancer Res
, vol.48
, pp. 4107-4112
-
-
Tondini, C.1
Hayes, D.F.2
Gelman, R.3
Henderson, I.C.4
Kufe, D.W.5
-
25
-
-
0033572338
-
The generation of endostatin is mediated by elastase
-
1:CAS:528:DC%2BD3cXktFyisg%3D%3D 10626789
-
W Wen MA Moses D Wiederschain JL Arbiser J Folyman 1999 The generation of endostatin is mediated by elastase Cancer Res 59 6052 6056 1:CAS:528: DC%2BD3cXktFyisg%3D%3D 10626789
-
(1999)
Cancer Res
, vol.59
, pp. 6052-6056
-
-
Wen, W.1
Moses, M.A.2
Wiederschain, D.3
Arbiser, J.L.4
Folyman, J.5
-
26
-
-
4444286921
-
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
-
DOI 10.1093/annonc/mdh309
-
SS Yoon NH Segal AB Olshen MF Brennan S Singer 2004 Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma Ann Oncol 15 1261 1266 1:STN:280:DC%2BD2cznt1Wltw%3D%3D 10.1093/annonc/mdh309 15277268 (Pubitemid 39199315)
-
(2004)
Annals of Oncology
, vol.15
, Issue.8
, pp. 1261-1266
-
-
Yoon, S.S.1
Segal, N.H.2
Olshen, A.B.3
Brennan, M.F.4
Singer, S.5
-
27
-
-
1642482608
-
Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer
-
DOI 10.1016/j.canlet.2003.09.018
-
JH Zhao F Yan HX Ju JH Tang JW Qin XS Zhao 2004 Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer Cancer Lett 204 87 95 1:CAS:528:DC%2BD2cXntV2jsg%3D%3D 10.1016/j.canlet.2003.09.018 14744538 (Pubitemid 38117197)
-
(2004)
Cancer Letters
, vol.204
, Issue.1
, pp. 87-95
-
-
Zhao, J.1
Yan, F.2
Ju, H.3
Tang, J.4
Qin, J.5
-
28
-
-
19544365867
-
The expression VEGF and Endostatin both in tissues and sera and the angiogenesis of breast cancer
-
1:CAS:528:DC%2BD2MXhtFyjtLnK
-
JH Zhao JH Tang FQ Meng JW Qin XS Zhao 2005 The expression VEGF and Endostatin both in tissues and sera and the angiogenesis of breast cancer Chin J Clin Oncol 32 79 82 1:CAS:528:DC%2BD2MXhtFyjtLnK
-
(2005)
Chin J Clin Oncol
, vol.32
, pp. 79-82
-
-
Zhao, J.H.1
Tang, J.H.2
Meng, F.Q.3
Qin, J.W.4
Zhao, X.S.5
|